Senaste uppdateringen :
19/11/2024
cancerläkemedel   Dacarbazine  
injektion
Lösningars stabilitet Stabilitet i blandningar Faktorer som påverkar stabiliteten Kompatibilitet Administreringssätt Hänvisningar pdf
   Molekylstruktur  

Varunamn   Varunamn     

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Acocarb Mexiko
Celdaz Indien, Peru
Dabaz Indien
Dacarb Indien, Peru
Dacarba Indien
Dacarbaz Turkiet
Dacarbazin Malaysia, Österrike, Polen, Ungern
Dacarbazina Argentina, Chile, Colombia, Ecuador, Spanien
Dacarbazine Australien, Belgien, Danmark, Förenta Staterna, Indien, Iran, Irland, Kanada, nya Zeeland, Storbritannien, Sverige
Dacarex Indien, Peru
Dacarin Indien
Dacarpalm Peru
Dacarzine Indien
Dacatic Finland
Dacin Schweiz
Dacmed Indien
Daracina Colombia
Deticene Frankrike, Grekland, Italien, Nederländerna, Saudi-Arabien, Tunisien
Detilem Mexiko
Detimedac Colombia, Tyskland
DTI Malaysia
DTIC Australien, Förenta Staterna, nya Zeeland, Österrike, Storbritannien, Sverige
Fauldetic Portugal
Ifadac Mexiko
Oncocarbil Argentina, Ecuador, Peru
Tiferomed Mexiko
Hänvisningar   injektion   Hänvisningar : Dacarbazine  
Typ Publikation
3 tidningen Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26 tidningen Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
40 tidningen Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC.
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Pharm Sci Communications 1994 ; 4: 97-101.
57 tidningen Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 tidningen Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 tidningen Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 tidningen Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 tidningen Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 tidningen Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 tidningen Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 tidningen Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 tidningen Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 tidningen Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 tidningen Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 tidningen Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 tidningen Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
353 tidningen Lunn G, Sansone EB.
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid.
Am J Hosp Pharm 1987 ; 44: 2519-2524.
492 tidningen Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
860 tidningen Nelson RW, Young R, Lamnin M.
Visual incompatibility of dacarbazine and heparin.
Am J Hosp Pharm 1987 ; 44: 2028.
905 tidningen Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1383 tidningen Stevens MFG, Peatey L.
Photodegradation of solutions of the antitumour drug DTIC.
J Pharm Pharmacol 1978 ; 30: 47P.
1410 tidningen Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1501 tidningen Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1635 tidningen El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F.
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags.
Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107 tidningen Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
3266 Laboratorium Lipomed Laboratories
Dacarbazine solutions: In Use stability of dacarbazine lipomed®
Lipomed 2011
3267 Laboratorium Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed 2011
3540 Laboratorium Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3605 Laboratorium Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
Lipomed 2010

  Mentions Légales